应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06955 博安生物
休市中 07-19 16:08:12
9.040
+0.010
+0.11%
最高
9.080
最低
8.940
成交量
13.32万
今开
9.030
昨收
9.030
日振幅
1.55%
总市值
46.04亿
流通市值
46.04亿
总股本
5.09亿
成交额
120.09万
换手率
0.03%
流通股本
5.09亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
博安生物(06955.HK)阿柏西普眼内注射溶液上市申请獾受理
阿斯达克财经 · 07-17
博安生物(06955.HK)阿柏西普眼内注射溶液上市申请獾受理
博安生物(06955):阿柏西普眼内注射溶液(BA9101)在中国上市申请获受理
智通财经 · 07-16
博安生物(06955):阿柏西普眼内注射溶液(BA9101)在中国上市申请获受理
博安生物(06955)下跌5.01%,报8.91元/股
金融界 · 06-06
博安生物(06955)下跌5.01%,报8.91元/股
博安生物盘中异动 股价大跌5.01%
自选股智能写手 · 06-06
博安生物盘中异动 股价大跌5.01%
博安生物(06955)股价下跌5.011%,现价港币$8.91
阿斯达克财经 · 06-06
博安生物(06955)股价下跌5.011%,现价港币$8.91
博安生物(06955)上涨5.62%,报9.58元/股
金融界 · 06-04
博安生物(06955)上涨5.62%,报9.58元/股
博安生物盘中异动 快速拉升5.62%
自选股智能写手 · 06-04
博安生物盘中异动 快速拉升5.62%
博安生物自主研发的度拉糖肽注射液的上市申请已获受理
新浪港股 · 05-28
博安生物自主研发的度拉糖肽注射液的上市申请已获受理
博安生物(06955.HK)度拉糖肽注射液上市申请获受理
阿斯达克财经 · 05-27
博安生物(06955.HK)度拉糖肽注射液上市申请获受理
博安生物(06955)自主研发的度拉糖肽注射液(BA5101)的上市申请已获受理
智通财经 · 05-27
博安生物(06955)自主研发的度拉糖肽注射液(BA5101)的上市申请已获受理
博安生物肿瘤领域地舒单抗注射液博洛加®在中国获批上市
美通社 · 05-27
博安生物肿瘤领域地舒单抗注射液博洛加®在中国获批上市
博安生物(06955):肿瘤领域地舒单抗注射液(120mg)-博洛加®获国家药监局批准上市
智通财经 · 05-27
博安生物(06955):肿瘤领域地舒单抗注射液(120mg)-博洛加®获国家药监局批准上市
【港股通】博安生物(06955):肿瘤领域地舒单抗注射液获国家药监局批准上市
金吾财讯 · 05-27
【港股通】博安生物(06955):肿瘤领域地舒单抗注射液获国家药监局批准上市
博安生物盘中异动 早盘急速拉升5.08%报9.921港元
自选股智能写手 · 05-27
博安生物盘中异动 早盘急速拉升5.08%报9.921港元
博安生物(06955)上涨5.62%,报10.9元/股
金融界 · 05-03
博安生物(06955)上涨5.62%,报10.9元/股
博安生物盘中异动 急速上涨5.04%
自选股智能写手 · 05-03
博安生物盘中异动 急速上涨5.04%
博安生物盘中异动 快速上涨5.13%
自选股智能写手 · 04-30
博安生物盘中异动 快速上涨5.13%
博安生物(06955)股价上升5.128%,现价港币$10.66
阿斯达克财经 · 04-30
博安生物(06955)股价上升5.128%,现价港币$10.66
博安生物(06955)上涨5.0%,报10.5元/股
金融界 · 04-29
博安生物(06955)上涨5.0%,报10.5元/股
博安生物盘中异动 下午盘股价大涨5.00%
自选股智能写手 · 04-29
博安生物盘中异动 下午盘股价大涨5.00%
加载更多
公司概况
公司名称:
博安生物
所属市场:
SEHK
上市日期:
--
主营业务:
山东博安生物技术股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事治疗用抗体的开发、生产和商业化,专注于肿瘤学、代谢学、自身免疫学和眼科等治疗领域。该公司主要拥有三个技术平台:全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联(ADC)技术平台。该公司主要在中国国内市场和海外市场开展其业务。
发行价格:
--
{"stockData":{"symbol":"06955","market":"HK","secType":"STK","nameCN":"博安生物","latestPrice":9.04,"timestamp":1721376492019,"preClose":9.03,"halted":0,"volume":133200,"delay":0,"floatShares":509278094,"shares":509278094,"eps":-0.25179383,"marketStatus":"休市中","marketStatusCode":7,"change":0.01,"latestTime":"07-19 16:08:12","open":9.03,"high":9.08,"low":8.94,"amount":1200858,"amplitude":0.015504,"askPrice":9.04,"askSize":200,"bidPrice":8.97,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.25179384114288395,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721611800000},"adr":0,"listingDate":1672329600000,"adjPreClose":9.03,"openAndCloseTimeList":[[1721352600000,1721361600000],[1721365200000,1721376000000]],"volumeRatio":0.8694516975819591,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06955","defaultTab":"news","newsList":[{"id":"2452910129","title":"博安生物(06955.HK)阿柏西普眼内注射溶液上市申请獾受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452910129","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452910129?lang=zh_cn&edition=full","pubTime":"2024-07-17 00:53","pubTimestamp":1721148780,"startTime":"0","endTime":"0","summary":"博安生物(06955.HK) 公布,公司自主研发的阿柏西普眼内注射溶液“BA9101”上市申请已获中国国家药品监督管理局药品审评中心受理。BA9101为艾力雅(EYLEA)的生物类似药,拟用于治疗成人新生血管(湿性)年龄相关性黄斑变性及糖尿病性黄斑水肿。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230112143756301_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230112143756301_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364087/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2451896055","title":"博安生物(06955):阿柏西普眼内注射溶液(BA9101)在中国上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2451896055","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451896055?lang=zh_cn&edition=full","pubTime":"2024-07-16 19:04","pubTimestamp":1721127850,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博安生物 发布公告,公司自主研发的阿柏西普眼内注射溶液的上市申请已获中国国家药品监督管理局药品审评中心受理。艾力雅2018年在中国获批上市,适应症为nAMD和DME。根据CDE发布的《生物类似药相似性评价和适应症外推技术指导塬则》,BA9101可申请获批艾力雅在中国获批的全部适应症。BA9101遵循生物类似药相关研究指南进行研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2441558927","title":"博安生物(06955)下跌5.01%,报8.91元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2441558927","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441558927?lang=zh_cn&edition=full","pubTime":"2024-06-06 11:10","pubTimestamp":1717643416,"startTime":"0","endTime":"0","summary":"6月6日,博安生物(06955)盘中下跌5.01%,截至11:10,报8.91元/股,成交108.2万元。山东博安生物技术股份有限公司是一家专业从事治疗用抗体开发的公司,主要服务领域包括肿瘤、代谢、自身免疫及眼科等。目前,公司已有2种商业化产品和12种在研药物,同时在中国、美国和欧盟市场开展生物产品开发。截至2023年年报,博安生物营业总收入6.18亿元、净利润-1.19亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/06111040924083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2441416753","title":"博安生物盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441416753","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441416753?lang=zh_cn&edition=full","pubTime":"2024-06-06 11:10","pubTimestamp":1717643410,"startTime":"0","endTime":"0","summary":"2024年06月06日早盘11时10分,博安生物股票出现异动,股价大幅下挫5.01%。截至发稿,该股报8.911港元/股,成交量11.86万股,换手率0.02%,振幅5.12%。资金方面,该股资金流入60.5302万港元,流出13.4684万港元。博安生物股票所在的生物技术行业中,整体涨幅为0.06%。其相关个股中,迈博药业-B、北海康成-B、奥星生命科技涨幅较大,振幅较大的相关个股有康宁杰瑞制药-B、科济药业-B、云顶新耀-B,振幅分别为10.93%、8.09%、7.88%。该公司在中国和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240606111010af8c4c49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240606111010af8c4c49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2441755628","title":"博安生物(06955)股价下跌5.011%,现价港币$8.91","url":"https://stock-news.laohu8.com/highlight/detail?id=2441755628","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441755628?lang=zh_cn&edition=full","pubTime":"2024-06-06 11:10","pubTimestamp":1717643400,"startTime":"0","endTime":"0","summary":"[下跌股]博安生物(06955) 股价在上午11:10比前收市价下跌5.011%,现股价为港币$8.91。至目前为止,今日最高价为$9.38,而最低价为$8.91。总成交量为10.18万股,总成交金额为港币$93.234万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD240606874/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2440547997","title":"博安生物(06955)上涨5.62%,报9.58元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2440547997","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440547997?lang=zh_cn&edition=full","pubTime":"2024-06-04 13:45","pubTimestamp":1717479913,"startTime":"0","endTime":"0","summary":"6月4日,博安生物(06955)盘中上涨5.62%,截至13:45,报9.58元/股,成交219.03万元。山东博安生物技术股份有限公司是一家专业从事治疗用抗体开发的公司,主要服务领域包括肿瘤、代谢、自身免疫及眼科等。目前,公司已有2种商业化产品和12种在研药物,同时在中国、美国和欧盟市场开展生物产品开发。截至2023年年报,博安生物营业总收入6.18亿元、净利润-1.19亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/04134540888602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2440647918","title":"博安生物盘中异动 快速拉升5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440647918","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440647918?lang=zh_cn&edition=full","pubTime":"2024-06-04 13:45","pubTimestamp":1717479906,"startTime":"0","endTime":"0","summary":"2024年06月04日下午盘13时45分,博安生物股票出现异动,股价大幅拉升5.62%。截至发稿,该股报9.581港元/股,成交量23.96万股,换手率0.05%,振幅7.50%。机构评级方面,在所有1家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。博安生物股票所在的生物技术行业中,整体涨幅为1.45%。博安生物公司简介:山东博安生物技术股份有限公司是一家主要从事生物制品开发、制造和商业化的中国公司。该公司在中国和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604134507af8bd9bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240604134507af8bd9bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2438136553","title":"博安生物自主研发的度拉糖肽注射液的上市申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2438136553","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438136553?lang=zh_cn&edition=full","pubTime":"2024-05-28 07:29","pubTimestamp":1716852573,"startTime":"0","endTime":"0","summary":"博安生物(06955)公布,公司自主研发的度拉糖肽注射液(BA5101)的上市申请已获中国国家药品监督管理局药品审评中心受理。\n 据悉,BA5101为度易达®(Trulicity®)的生物类似药,用于成人2型糖尿病患者的血糖控制。就本公司所知,BA5101是目前中国首个提交上市申请的度易达®(Trulicity®)生物类似药,也是全球首个完成Ⅲ期临床试验的度易达®(Trulicity®)生物类似药,开发进度领先。除了在中国,该产品的国际注册和临床也在积极推进中。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-28/doc-inawtrfv3173134.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-28/doc-inawtrfv3173134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2438333897","title":"博安生物(06955.HK)度拉糖肽注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2438333897","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438333897?lang=zh_cn&edition=full","pubTime":"2024-05-27 22:42","pubTimestamp":1716820920,"startTime":"0","endTime":"0","summary":"博安生物(06955.HK) 公布,公司自主研发的度拉糖肽注射液(BA5101)上市申请已获中国国家药品监督管理局药品审评中心受 理。BA5101为度易达(Trulicity)的生物类似药,用于成人2型糖尿病患者的血糖控制。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230112143754598_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230112143754598_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352399/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2438686384","title":"博安生物(06955)自主研发的度拉糖肽注射液(BA5101)的上市申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2438686384","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438686384?lang=zh_cn&edition=full","pubTime":"2024-05-27 20:56","pubTimestamp":1716814618,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博安生物 公布,公司自主研发的度拉糖肽注射液的上市申请已获中华人民共和国国家药品监督管理局药品审评中心受理。据悉,BA5101为度易达的生物类似药,用于成人2型糖尿病患者的血糖控制。就本公司所知,BA5101是目前中国首个提交上市申请的度易达生物类似药,也是全球首个完成Ⅲ期临床试验的度易达生物类似药,开发进度领先。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2438873316","title":"博安生物肿瘤领域地舒单抗注射液博洛加®在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2438873316","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438873316?lang=zh_cn&edition=full","pubTime":"2024-05-27 13:54","pubTimestamp":1716789240,"startTime":"0","endTime":"0","summary":"中国市场以外,博安生物亦在欧洲、美国、日本开展博洛加的国际多中心Ⅲ期临床试验,并计划在全球更多国家和地区上市该产品。目前,博安生物已有三款产品获批上市,以及多个具有国际知识产权保护的创新型生物药和生物类似药的在研产品组合。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4423754_ZH23754_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1066053197.SGD","LU1059921491.USD","LU0868494617.USD","BK4231","LU1430594728.SGD","LU0234570918.USD","BK4527","LU1506573853.SGD","LU2286300806.USD","BK4581","LU1571399168.USD","LU1585245621.USD","IE00BSNM7G36.USD","BK4533","BK4579","BK4588","06955","BK4560","BK1161","ADC","IE00BKVL7J92.USD","LU1244550221.USD","LU1599440770.SGD","SG9999001440.SGD","BK4525","LU0731783394.SGD","LU0348723411.USD","LU0234572021.USD","LU1244550577.SGD","BK4020","BK4534","IE00BZ1G4Q59.USD","SG9999001424.SGD","CSCO","BK4585","SG9999002232.USD","SG9999002224.SGD","LU1066051498.USD","LU1244550494.USD","BK4515","BK4080","BK4550"],"gpt_icon":0},{"id":"2438217728","title":"博安生物(06955):肿瘤领域地舒单抗注射液(120mg)-博洛加®获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2438217728","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438217728?lang=zh_cn&edition=full","pubTime":"2024-05-27 12:28","pubTimestamp":1716784130,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博安生物 发布公告,公司自主研发的肿瘤领域地舒单抗注射液-博洛加已获中国国家药品监督管理局批准上市,用于治疗不可手术切除或者手术切除可能导致严重功能障碍的骨巨细胞瘤,包括成人和骨胳发育成熟的青少年患者。公司也在推进博洛加用于实体肿瘤骨转移和多发性骨髓瘤适应症的中国上市工作。公告称,在庞大的患者需求以及良好的临床价值等多种因素的共同推动下,博洛加在全球范围内将具有广阔的市场前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1126337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2438821606","title":"【港股通】博安生物(06955):肿瘤领域地舒单抗注射液获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2438821606","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438821606?lang=zh_cn&edition=full","pubTime":"2024-05-27 12:17","pubTimestamp":1716783454,"startTime":"0","endTime":"0","summary":"本公司也在推进博洛加用于实体肿瘤骨转移和多发性骨髓瘤适应症的中国上市工作。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NzBjNjFmNjI4ZDIyNTQ0NjcwODk0MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NzBjNjFmNjI4ZDIyNTQ0NjcwODk0MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1937554","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06955","YANG","HSCEI","07226","BK1161","HSTECH"],"gpt_icon":0},{"id":"2438841442","title":"博安生物盘中异动 早盘急速拉升5.08%报9.921港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2438841442","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438841442?lang=zh_cn&edition=full","pubTime":"2024-05-27 09:31","pubTimestamp":1716773485,"startTime":"0","endTime":"0","summary":"2024年05月27日早盘09时31分,博安生物股票出现波动,股价大幅拉升5.08%。截至发稿,该股报9.921港元/股,成交量9200股,换手率0.00%,振幅0.21%。资金方面,该股资金流入6.7372万港元,流出2.3796万港元。博安生物股票所在的生物技术行业中,整体涨幅为0.05%。其相关个股中,博安生物、君实生物、乐普生物-B涨幅较大,振幅较大的相关个股有乐普生物-B、康方生物、荣昌生物,振幅分别为10.27%、3.51%、3.50%。该公司在中国和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240527093126aef1bdce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240527093126aef1bdce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2432178219","title":"博安生物(06955)上涨5.62%,报10.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432178219","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432178219?lang=zh_cn&edition=full","pubTime":"2024-05-03 13:37","pubTimestamp":1714714647,"startTime":"0","endTime":"0","summary":"5月3日,博安生物(06955)盘中上涨5.62%,截至13:37,报10.9元/股,成交117.02万元。山东博安生物技术股份有限公司是一家专业从事治疗用抗体开发的公司,主要服务领域包括肿瘤、代谢、自身免疫及眼科等。目前,公司已有2种商业化产品和12种在研药物,同时在中国、美国和欧盟市场开展生物产品开发。截至2023年年报,博安生物营业总收入6.18亿元、净利润-1.19亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/03133740514066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2432918613","title":"博安生物盘中异动 急速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432918613","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432918613?lang=zh_cn&edition=full","pubTime":"2024-05-03 11:10","pubTimestamp":1714705816,"startTime":"0","endTime":"0","summary":"2024年05月03日早盘11时10分,博安生物股票出现波动,股价急速上涨5.04%。截至发稿,该股报10.841港元/股,成交量8.06万股,换手率0.02%,振幅6.59%。博安生物股票所在的生物技术行业中,整体跌幅为0.83%。其相关个股中,美因基因、创胜集团-B、和铂医药-B涨幅较大,振幅较大的相关个股有圣诺医药-B、药明合联、美因基因,振幅分别为17.65%、13.02%、12.83%。该公司在中国和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405031110167a57f569&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405031110167a57f569&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2431494358","title":"博安生物盘中异动 快速上涨5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431494358","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431494358?lang=zh_cn&edition=full","pubTime":"2024-04-30 13:09","pubTimestamp":1714453781,"startTime":"0","endTime":"0","summary":"2024年04月30日下午盘13时09分,博安生物股票出现异动,股价急速拉升5.13%。截至发稿,该股报10.661港元/股,成交量7.48万股,换手率0.01%,振幅5.13%。博安生物股票所在的生物技术行业中,整体跌幅为0.43%。其相关个股中,北海康成-B、博安生物、科济药业-B涨幅较大,振幅较大的相关个股有科笛-B、乐普生物-B、科伦博泰生物-B,振幅分别为27.56%、15.86%、13.64%。该公司在中国和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430130941861ea529&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240430130941861ea529&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2431735819","title":"博安生物(06955)股价上升5.128%,现价港币$10.66","url":"https://stock-news.laohu8.com/highlight/detail?id=2431735819","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431735819?lang=zh_cn&edition=full","pubTime":"2024-04-30 13:09","pubTimestamp":1714453740,"startTime":"0","endTime":"0","summary":"[上升股]博安生物(06955) 股价在下午01:09比前收市价上升5.128%,现股价为港币$10.66。至目前为止,今日最高价为$10.66,而最低价为$10.14。总成交量为7.48万股,总成交金额为港币$76.984万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240430871/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06955"],"gpt_icon":0},{"id":"2431083260","title":"博安生物(06955)上涨5.0%,报10.5元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431083260","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431083260?lang=zh_cn&edition=full","pubTime":"2024-04-29 14:41","pubTimestamp":1714372896,"startTime":"0","endTime":"0","summary":"4月29日,博安生物(06955)盘中上涨5.0%,截至14:41,报10.5元/股,成交164.91万元。山东博安生物技术股份有限公司是一家专业从事治疗用抗体开发的公司,主要服务领域包括肿瘤、代谢、自身免疫及眼科等。目前,公司已有2种商业化产品和12种在研药物,同时在中国、美国和欧盟市场开展生物产品开发。截至2023年年报,博安生物营业总收入6.18亿元、净利润-1.19亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29144140463171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06955","BK1161"],"gpt_icon":0},{"id":"2431925008","title":"博安生物盘中异动 下午盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431925008","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431925008?lang=zh_cn&edition=full","pubTime":"2024-04-29 14:41","pubTimestamp":1714372893,"startTime":"0","endTime":"0","summary":"2024年04月29日下午盘14时41分,博安生物股票出现异动,股价大幅拉升5.00%。截至发稿,该股报10.501港元/股,成交量16.2万股,换手率0.03%,振幅7.80%。机构评级方面,在所有1家参与评级的机构中,100%的券商给予持有建议,无券商给予买入、卖出建议。博安生物股票所在的生物技术行业中,整体涨幅为1.02%。该公司在中国和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291441347a56f11b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404291441347a56f11b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06955"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.boan-bio.com","stockEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0238},{"period":"3month","weight":-0.0887},{"period":"6month","weight":-0.2056},{"period":"1year","weight":-0.4322},{"period":"ytd","weight":-0.4168}],"compareEarnings":[{"period":"1week","weight":-0.0479},{"period":"1month","weight":-0.0549},{"period":"3month","weight":0.0736},{"period":"6month","weight":0.1378},{"period":"1year","weight":-0.0798},{"period":"ytd","weight":0.0217}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东博安生物技术股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事治疗用抗体的开发、生产和商业化,专注于肿瘤学、代谢学、自身免疫学和眼科等治疗领域。该公司主要拥有三个技术平台:全人抗体转基因小鼠及噬菌体展示技术平台、双特异T-cell Engager技术平台、抗体药物偶联(ADC)技术平台。该公司主要在中国国内市场和海外市场开展其业务。","exchange":"SEHK","name":"博安生物","nameEN":"BOAN BIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博安生物,06955,博安生物股票,博安生物股票老虎,博安生物股票老虎国际,博安生物行情,博安生物股票行情,博安生物股价,博安生物股市,博安生物股票价格,博安生物股票交易,博安生物股票购买,博安生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博安生物(06955)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博安生物(06955)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}